Stein Gary E
Department of Medicine, Michigan State University, East Lansing, MI 48824, USA.
Clin Infect Dis. 2005 Sep 1;41 Suppl 5:S293-302. doi: 10.1086/431671.
Several parenteral antimicrobials have been introduced into clinical practice over the course of the last decade. Some of these agents (e.g., linezolid, daptomycin, and tigecycline) are prototypes of new classes of compounds. In comparative clinical trials, these newer anti-infectives have been shown to be safe and to have low rates of discontinuation by patients. However, long-term use has revealed unique toxicities associated with the use of some of these drugs. The adverse events and potential drug interactions associated with the use of these antibiotics are variable and require familiarity with the safety profile of each drug. It is especially important that clinicians be able to recognize serious adverse events associated with the use of specific drugs, because most of the adverse events can be readily reversed by cessation of therapy.
在过去十年中，几种肠胃外抗菌药物已被引入临床实践。其中一些药物（如利奈唑胺、达托霉素和替加环素）是新型化合物类别的原型。在比较临床试验中，这些较新的抗感染药物已被证明是安全的，患者停药率较低。然而，长期使用已揭示出与其中一些药物使用相关的独特毒性。与这些抗生素使用相关的不良事件和潜在药物相互作用各不相同，需要熟悉每种药物的安全性概况。临床医生能够识别与特定药物使用相关的严重不良事件尤为重要，因为大多数不良事件通过停止治疗可以很容易地逆转。
